These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8493429)

  • 1. Interim analyses, stopping rules and data monitoring in clinical trials in Europe.
    Buyse M
    Stat Med; 1993 Mar; 12(5-6):509-20. PubMed ID: 8493429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Policies for study monitoring and interim reporting of results.
    Green SJ; Fleming TR; O'Fallon JR
    J Clin Oncol; 1987 Sep; 5(9):1477-84. PubMed ID: 3625262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A survey of monitoring practices in cancer clinical trials.
    George SL
    Stat Med; 1993 Mar; 12(5-6):435-50. PubMed ID: 8493422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of clinical trials and interim analyses from a drug sponsor's point of view.
    Williams GW; Davis RL; Getson AJ; Gould AL; Hwang IK; Matthews H; Shih WJ; Snapinn SM; Walton-Bowen KL
    Stat Med; 1993 Mar; 12(5-6):481-92. PubMed ID: 8493426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of external monitoring committees in clinical trials of the National Institute of Allergy and Infectious Diseases.
    Ellenberg SS; Myers MW; Blackwelder WC; Hoth DF
    Stat Med; 1993 Mar; 12(5-6):461-7; discussion 469. PubMed ID: 8493424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early stopping, interim analyses, and monitoring committees: what are the tradeoffs?
    Zelen M
    J Clin Oncol; 1987 Sep; 5(9):1314-5. PubMed ID: 3625252
    [No Abstract]   [Full Text] [Related]  

  • 7. Monitoring clinical trials: experience of, and proposals under consideration by, the Cancer Therapy Committee of the British Medical Research Council.
    Parmar MK; Machin D
    Stat Med; 1993 Mar; 12(5-6):497-504. PubMed ID: 8493427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know.
    Neaton JD; Grund B; Wentworth D
    Clin Trials; 2018 Aug; 15(4):359-365. PubMed ID: 29552920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?
    Bryant J
    Stat Med; 2004 May; 23(10):1507-11. PubMed ID: 15122728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
    Stegert M; Kasenda B; von Elm E; You JJ; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Briel M;
    J Clin Epidemiol; 2016 Jan; 69():152-60. PubMed ID: 26361993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Data monitoring committees and interim monitoring guidelines.
    Freidlin B; Korn EL; George SL
    Control Clin Trials; 1999 Oct; 20(5):395-407. PubMed ID: 10503800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stopping rules, interim analyses and data monitoring committees.
    Ashby D; Machin D
    Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
    [No Abstract]   [Full Text] [Related]  

  • 13. Data monitoring committees: the moral case for maximum feasible independence.
    Walters L
    Stat Med; 1993 Mar; 12(5-6):575-80; discussion 581-2. PubMed ID: 8493433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A major trial needs three statisticians: why, how and who?
    Pocock SJ
    Stat Med; 2004 May; 23(10):1535-9. PubMed ID: 15122734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trials stopped early for benefit: a systematic review.
    Montori VM; Devereaux PJ; Adhikari NK; Burns KE; Eggert CH; Briel M; Lacchetti C; Leung TW; Darling E; Bryant DM; Bucher HC; Schünemann HJ; Meade MO; Cook DJ; Erwin PJ; Sood A; Sood R; Lo B; Thompson CA; Zhou Q; Mills E; Guyatt GH
    JAMA; 2005 Nov; 294(17):2203-9. PubMed ID: 16264162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independence of the statistician who analyses unblinded data.
    Siegel JP; O'Neill RT; Temple R; Campbell G; Foulkes MA
    Stat Med; 2004 May; 23(10):1527-9. PubMed ID: 15122732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Data monitoring committees for Southwest Oncology Group clinical trials.
    Green S; Crowley J
    Stat Med; 1993 Mar; 12(5-6):451-5. PubMed ID: 8493423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accounting for interim safety monitoring of an adverse event upon termination of a clinical trial.
    Dallas MJ
    J Biopharm Stat; 2008; 18(4):631-8; discussion 439-45. PubMed ID: 18607795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of clinical trials: issues and recommendations.
    Fleming TR; DeMets DL
    Control Clin Trials; 1993 Jun; 14(3):183-97. PubMed ID: 8339549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.